Personalized health is neither a fad nor a luxury: it is the natural evolution of preventive medicine, made possible by large population cohorts, new biomarkers and better-calibrated risk scores. Every week in our practice, we see healthy adults who want to “take stock” without knowing where to start. This guide explains what personalized health covers, what it actually offers, where its limits lie and how it fits with the care pathway covered by French National Health Insurance (Assurance Maladie).
What is personalized health?
Personalized health is an approach to prevention that tailors advice, screening and follow-up to a person’s own characteristics: age, sex, family history, lifestyle and biomarkers. It stands in contrast to “one-size-fits-all” prevention, in which everyone receives the same messages at the same time. Its goal is not to multiply tests, but to offer the right ones, to the right person, at the right time.
Three related concepts are worth distinguishing, because they partly overlap.
Personalized medicine: definition
Personalized medicine is the practice of adjusting care (prevention, diagnosis, treatment) to the individual patient’s profile rather than to a population average. The term originated in oncology, where the choice of treatment now depends on the molecular characteristics of the tumor. Applied to prevention, personalized medicine means estimating an individual risk, then prioritizing the actions that matter for that particular person.
Precision medicine
Precision medicine refers to the use of detailed biological data (genome, proteins, metabolites, imaging) to characterize an individual at a higher resolution than a standard clinical examination. It is the technical toolkit of personalized medicine: more measurements, better quantified. Precise measurements do not, however, guarantee relevant decisions; we will come back to this.
Predictive medicine
Predictive medicine seeks to estimate, before any symptoms appear, the probability that a person will develop a disease within a given time frame, for example 10 years. It relies on statistical models built on large populations. A prediction is never a certainty: it gives an order of magnitude that helps with decisions, not a verdict.
In practice, personalized health combines these three dimensions to serve a single question: what can I, personally, do to stay healthy for longer?
What are the 4 types of prevention?
Four types of prevention are traditionally distinguished: primary, secondary, tertiary and quaternary. The World Health Organization (WHO) defines prevention as all measures aimed at avoiding or reducing the number and severity of diseases, injuries and disabilities. The four levels complement each other, and a single consultation may draw on several of them.
| Type of prevention | When does it apply? | Goal | Examples |
|---|---|---|---|
| Primary | Before the disease develops | Prevent the disease from occurring | Vaccination, quitting smoking, physical activity, diet |
| Secondary | Early-stage disease, without symptoms | Detect it early to act before complications | Organized cancer screening programs, blood pressure measurement, blood glucose |
| Tertiary | Established disease | Limit complications, recurrences and disability | Cardiac rehabilitation, therapeutic patient education, diabetes follow-up |
| Quaternary | At any time | Protect against unnecessary or harmful tests and treatments | Not ordering a test that serves no purpose, explaining false positives |
Quaternary prevention, formalized by the Belgian general practitioner Marc Jamoulle, is the least known of the four and yet the most useful for thinking about personalized health. It reminds us that no test is ever neutral: it can falsely reassure, needlessly worry or trigger a cascade of investigations. Personalizing prevention therefore also means knowing when not to act.
The four types of prevention are defined term by term in our prevention glossary.
4P medicine: what do predictive, preventive, personalized and participatory mean?
4P medicine is a framework that describes the medicine of the future as predictive, preventive, personalized and participatory. The phrase was popularized in the 2000s by the American biologist Leroy Hood, a pioneer of systems biology. Some authors add a fifth P (5P medicine), whose definition varies: pertinence, proof or a population dimension, depending on the source.
- Predictive: estimating a person’s risks from their data (history, biomarkers, sometimes genome) rather than waiting for symptoms.
- Preventive: turning that estimate into concrete actions before disease sets in.
- Personalized: adapting those actions to the person’s profile and priorities.
- Participatory: involving the patient in decisions, with understandable information, in a shared decision-making approach.
The fourth P is often the most neglected. Yet it is what distinguishes genuine personalized health from a mere pile of results: without time for a conversation in which the person understands their numbers and chooses their priorities, the prediction goes nowhere.
What has changed in personalized preventive medicine over the past ten years?
Three developments have moved personalized preventive medicine from concept to practice: large population cohorts, metabolomics and recalibrated risk scores. None of these advances stands alone; it is their combination that now makes it possible to estimate an individual risk with more nuance than in 2015.
Large cohorts such as UK Biobank
UK Biobank is a British cohort of about 500,000 volunteers aged 40 to 69 at recruitment, between 2006 and 2010, followed for at least thirty years. Genomic data, imaging, health records and, since 2021, nuclear magnetic resonance (NMR) metabolomic profiles are linked together. More than 9,000 peer-reviewed publications had drawn on it as of November 2023. It is on this type of cohort that researchers can measure, at scale, which biomarker signals which disease, and with what margin of error.
Blood metabolomics
Metabolomics consists of simultaneously measuring dozens or hundreds of small molecules and lipids circulating in the blood. The NMR panel developed by Nightingale Health (Helsinki) quantifies 249 biomarkers from a single blood sample: lipoproteins by class and size, fatty acids, amino acids, glycolysis markers, ketone bodies and inflammation (GlycA). In UK Biobank, the analysis of 118,461 participants linked these biomarkers to more than 700 common diseases (Julkunen et al., Nature Communications, 2023). We describe this technology in detail in our article on NMR metabolomics and the markers themselves in the guide to blood biomarkers.
Recalibrated risk scores
A risk score combines a few variables (age, sex, smoking, blood pressure, cholesterol) to estimate the probability of an event over 10 years. In 2021, the European Society of Cardiology published SCORE2, for people aged 40–69, and SCORE2-OP, for those aged 70–89. They estimate the 10-year risk of a fatal or non-fatal cardiovascular event, calibrated by European region; France is in the low-risk region. These scores require only a handful of measurements: that is their strength in routine practice and their limitation when you want to go further. We explain how to read them in the article on 10-year cardiovascular risk.
What UK Biobank studies show
The study by Buergel and colleagues (Nature Medicine, 2022), conducted on 117,981 UK Biobank participants and validated in four independent cohorts, showed that a metabolomic profile from a single blood sample helps predict the 10-year onset of 24 common diseases (metabolic, vascular, respiratory and neurological diseases, and cancers). For eight of them, including type 2 diabetes, dementia and heart failure, this profile provided additional predictive information beyond the usual clinical variables. In other words, UK Biobank studies show that the metabolomic profile improves the prediction of 10-year risk for several diseases. This does not mean that it “detects” these diseases years in advance, a phrasing we do not use.
What can personalized health actually do for a healthy adult?
For an adult with no known disease, personalized health helps answer four questions: what are my priority risks, which screenings really apply to me, which habits have the greatest effect in my case, and how can I track my trajectory over time? It turns a one-off check-up into an action plan.
Prioritize rather than accumulate
A structured questionnaire on lifestyle habits, family history and subtle symptoms, supplemented by a few measurements (blood pressure, waist circumference, basic blood test), is often enough to identify one or two priority topics. This is in fact the approach of Mon bilan prévention, France’s national prevention check-up program, which includes a risk assessment, the joint selection of one or two priority topics, and a written Personalized Prevention Plan (PPP).
Estimate a risk rather than find a disease
Moving from “everything is fine” to “here is your level of cardiovascular and metabolic risk, and what influences it” changes the conversation. A score such as SCORE2 provides an initial estimate; a broader biomarker panel, when indicated, can refine that estimate by taking into account detailed lipoproteins, low-grade inflammation or the fatty acid profile. Here again, the aim is to estimate, not to diagnose.
Track a trajectory
The value of a single biomarker reading is limited. Its trajectory over several years, on the other hand, is telling: a marker that slowly worsens in a person without symptoms is information that “normal / abnormal” thresholds do not capture. Personalized health therefore takes a long-term view, with a point of comparison at each stage. Metabolic age is one example: a trajectory indicator, useful if it is properly understood.
Decide together
Finally, personalized health gives patients the means to participate: understanding what a number means, knowing what can and cannot be changed, and choosing their priorities. In our practice, we find that this understanding is the leading factor in adherence to a prevention plan.
Standard approach or personalized health: what are the differences?
The standard approach applies to everyone the recommendations that hold for their age group; personalized health starts from the same recommendations, then adjusts them to the individual profile. The two are not opposed: the second builds on the first.
| Dimension | Standard approach | Personalized approach |
|---|---|---|
| Starting point | Age group and sex | Individual profile: history, lifestyle, biomarkers |
| Risk assessment | Traditional risk factors, simple score (e.g., SCORE2) | Traditional score supplemented, if indicated, by extended biomarkers (metabolomics) |
| Tests | Standard list by age | Standard tests, then targeted tests based on estimated risk |
| What you receive | Lab report, reference values | Explained risk estimate, priorities, action plan |
| Follow-up | Occasional, at the pace of consultations | Trajectory over time, points of comparison |
| Patient’s role | Recipient of advice | Active participant in decisions (participatory medicine) |
| Main risk | Missing an atypical profile | Overmedicalization if tests are multiplied without indication |
What are the limits and pitfalls of personalized health?
Personalized health carries three risks: overmedicalization, overdiagnosis and the emergence of two-tier prevention. These risks are not theoretical; they are at the heart of the 2026 public debate in France over private check-ups.
Overmedicalization
The more you measure, the more you find. A panel of several hundred biomarkers almost always includes a few values outside the reference ranges, without this reflecting any disease. Without a doctor to interpret them, every value “in red” becomes a source of worry and further testing. Quaternary prevention means prescribing only what has a proven benefit for the person, and explaining why the rest is unnecessary.
Overdiagnosis
Overdiagnosis refers to the discovery of real abnormalities that would never have caused symptoms or shortened life. It is well documented for certain screening tests and potentially affects any strategy that looks for weak signals in people without symptoms. A risk estimate is not a diagnosis, and a marker associated with a disease in a cohort does not predict an individual’s future with certainty: probability applies to the population, decisions apply to the person.
Elite check-ups in the 2026 debate
Since the beginning of 2026, the French press has been questioning preventive health start-ups: franceinfo ran the headline “Le luxe de prévenir” (“The luxury of prevention”), Maddyness published “Zoï, Kor, Lucis : ces startups de la santé préventive qui font débat” (“Zoï, Kor, Lucis: the preventive health startups stirring debate”) on March 2, 2026, and What’s up Doc reported on check-ups costing “€3,600, not reimbursed.” Public prices recorded on September 14, 2026 range from €365 (Osyva’s Découverte program) and €490 per year (Lucis’s Care plan, two check-ups) to €990 (Zoī’s Pulse) and up to €18,000 (Zoī’s Ultimate). Each of these offerings has its merits and its audience, but the question raised by the debate is legitimate: prevention reserved for those who can pay for it widens health inequalities instead of reducing them, even though the people furthest from the healthcare system are often those who would need it most. We compare these offerings with the covered pathway in our comparison of private check-ups and the covered check-up.
Health data
Personalization requires collecting sensitive data. Its hosting, use and transmission to the patient’s regular doctor must be regulated (certified health data hosting, explicit consent, right to object). This is a selection criterion in its own right when turning to a private provider.
How do personalized health and the covered prevention check-up fit together?
The right order is simple: the prevention check-up covered by French National Health Insurance first, personalization second, in coordination with your regular doctor (médecin traitant). Personalized health is not an alternative to the care pathway; it is an extension of it.
The foundation: Mon bilan prévention
Since 2024, Mon bilan prévention has been offered at four key ages: 18 to 25, 45 to 50, 60 to 65 and 70 to 75 inclusive, with one check-up per person per age bracket. It is carried out by a doctor, nurse, pharmacist or midwife, lasts 30 to 45 minutes and is fully covered (100%) by French National Health Insurance, with no upfront payment. It includes a self-assessment questionnaire to complete before the appointment, a conversation to prioritize one or two topics, and a written Personalized Prevention Plan sent to the regular doctor unless the patient objects. Its framework is set by the French ministerial order of May 28, 2024 (arrêté du 28 mai 2024). We describe the program in detail in the guide to the prevention check-up.
In principle, the prevention check-up is already a personalized approach: it does not set out the same list of tests for everyone, but starts from the person’s habits and risks to build a plan. Its limitation is that of a 30- to 45-minute conversation: it does not include laboratory tests.
The complement: the preventive health examination
The preventive health examination (examen de prévention en santé, EPS), offered in about a hundred French National Health Insurance health examination centers, lasts about two hours and includes, depending on the person’s profile, a blood draw, a urine test, hearing and cardiorespiratory tests and a medical consultation. It is fully covered (100%) and intended primarily for people who are far removed from the healthcare system. It can be combined with Mon bilan prévention. See our article on the free health check and the preventive health examination.
Personalization: when and for whom?
A more in-depth analysis, such as a comprehensive blood test or a metabolomic panel, should be discussed with the doctor when an intermediate risk deserves to be clarified, when family history weighs heavily, or when a person wishes to track their trajectory over time. It makes no sense without medical interpretation or without feedback to the regular doctor, who remains the cornerstone of the care pathway. The principle is that of quaternary prevention: every additional test must be able to change a decision.
Who can support you in a personalized health approach?
Your regular doctor is your first point of contact; the professionals authorized to carry out the prevention check-up (nurses, pharmacists, midwives) are the entry point at the key ages; and structured services can prepare and extend this pathway. Three criteria help you judge the support on offer: a doctor interprets and signs the plan, your regular doctor is kept informed, and the approach starts with the covered pathway rather than with paid tests.
Key takeaways
- Personalized health tailors prevention to each person’s profile: risks, biomarkers, lifestyle habits and priorities.
- It rests on four types of prevention (primary, secondary, tertiary, quaternary) and on the 4P medicine framework, in which patient participation matters as much as prediction.
- Large cohorts such as UK Biobank and NMR metabolomics improve the estimate of 10-year risk for several diseases; they do not establish a diagnosis.
- Its pitfalls are overmedicalization, overdiagnosis and two-tier prevention, at the heart of the 2026 debate over private check-ups.
- The right order: the fully covered (100%) prevention check-up first, personalization second, always in coordination with your regular doctor.
What Sokrate lets you do
The Sokrate service prepares your prevention check-up online through an adaptive questionnaire (Sokrate 360, nine dimensions of health), after which a doctor writes and signs your Personalized Prevention Plan. A letter is sent to your regular doctor, unless you object, and a coordinating nurse handles follow-up. The prevention check-up carried out by an authorized professional is fully covered (100%) by French National Health Insurance, with no upfront payment. As an option, an NMR metabolomic analysis of 249 biomarkers, performed on the Nightingale Health platform and interpreted by a doctor, can refine the estimate of your risks. To understand the steps, see how the Sokrate pathway works or join the waitlist.